Effects of benzo(a)pyrene and nicotine on prostaglandin synthesis in buccal pouch and submandibular glands of the Syrian hamster.
Adult male Syrian hamsters were treated by swabbing the apex of the buccal pouch with corn oil (control, C), 1 mM benzo(a)pyrene (BP), nicotine (NC), or BP+NC in corn oil, twice daily, 5 days a week. After a 4-week treatment, the pouches and submandibular glands were dissected and used for the determination of endogenous prostaglandin (PG) production and studies on in vitro PG synthesis. Of the three PGs analysed (PGE2, PGF2 alpha and 6-keto-PGF1 alpha), PGE2 was predominant in the pouch and the glands. BP or NC alone had only a weak effect on PG synthesis in both tissues. However, the combination of BP and NC had a synergistic effect, causing diminished PG synthesis in both tissues. In buccal pouch, BP+NC significantly decreased the concentrations of endogenous PGE2 and PGF2 alpha (PGE2: 0.669 +/- 0.254 versus 1.698 +/- 0.460, PGF2 alpha: 0.273 +/- 0.090 versus 0.625 +/- 0.272 ng/g tissue; BP+NC versus C; mean +/- SD, n = 5, p < 0.05). Similarly significant results were also found for in vitro PG synthesis (PGE2: 0.541 +/- 0.249 versus 1.399 +/- 0.340, PGF2 alpha: 1.045 +/- 0.428 versus 2.133 +/- 0.510 ng/g tissue; BP+NC versus C; mean +/- SD, n = 5, p < 0.05). In submandibular glands, BP+NC significantly diminished the concentration of endogenous PGE2 (1.183 +/- 0.175 versus 2.379 +/- 0.488 ng/g tissue; BP+NC versus C; mean +/- SD, n = 5, p < 0.05). The synthesis of 6-keto-PGF1 alpha in both tissues, and the synthesis of PGF2 alpha in submandibular gland, were slightly decreased with all treatments.
Wu-Wang
C Y
CY
Dental Research Center, New Jersey Dental School, University of Medicine and Dentistry of New Jersey, Newark 07103.
Wang
S L
SL
Brigham
M
M
Correa
A
A
Slomiany
A
A
Slomiany
B L
BL
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000704:Analysis of Variance; D000818:Animals; D001564:Benzo(a)pyrene / Q000633:toxicity*; D002610:Cheek; D006224:Cricetinae; D015237:Dinoprost / Q000096:biosynthesis; D015232:Dinoprostone / Q000096:biosynthesis; D004357:Drug Synergism; D008297:Male; D008647:Mesocricetus; D009061:Mouth Mucosa / Q000187:drug effects* / Q000378:metabolism; D009538:Nicotine / Q000633:toxicity*; D011453:Prostaglandins / Q000096:biosynthesis*; D011863:Radioimmunoassay; D013363:Submandibular Gland / Q000187:drug effects* / Q000378:metabolism
D011453:Prostaglandins; D001564:Benzo(a)pyrene; D015121:6-Ketoprostaglandin F1 alpha; D009538:Nicotine; D015237:Dinoprost; D015232:Dinoprostone